Neurotoxicity associated with anti-PD1 therapy: A multi-center case series.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e21641
Abstract: e21641Background: The anti-PD1 antibodies (PD1) pembrolizumab and nivolumab are now FDA-approved in multiple malignancies. With increased use, rarer immune-related adverse events (irAEs) not well c... read more here.
Keywords: pd1 therapy; therapy multi; anti pd1; multi center ... See more keywords